Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR604 in Healthy Participants and Participants With Hemophilia A, Hemophilia B, or Factor VII Deficiency
NCT06349473Phase 1Recruiting
- Sponsor
- Equilibra Bioscience LLC
- Start
- May 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised trial of SR604 in hemophilia A, hemophilia B (HB) and Factor VII deficiency (8 cohorts), sponsored by Equilibra Bioscience LLC. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events at 3 months and Number of Participants with Clinical Abnormal Changes in Coagulations Markers at Day 90. Started May 2024; status: recruiting.
02
Drugs
SR604
03
Conditions
hemophilia Ahemophilia B (HB)Factor VII deficiency
Beyond the preview
Go deeper on NCT06349473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349473.